AOD-9604

AOD Peptide: Complete Guide for Medical Professionals

Unlike full‑length HGH, which affects multiple physiological systems, AOD‑9604 was engineered to target adipose tissue metabolism rather than global growth and anabolic signaling. This theoretical selectivity has generated interest among clinicians and researchers studying peptide‑based approaches to body composition and obesity, particularly in settings where growth‑promoting effects of HGH are not desired. However, it is essential to emphasize that AOD‑9604 remains an investigational peptide and is not approved for therapeutic or aesthetic use by major regulators, including the FDA, EMA, or TGA. Clinical development of AOD‑9604 as an obesity drug was discontinued after phase 2 trials failed to demonstrate sufficiently robust efficacy compared with placebo.

What Is AOD-9604?

AOD‑9604 is a synthetic peptide fragment derived from amino acids 176–191 of the C‑terminal region of human growth hormone. This segment was identified as a key domain for stimulating lipolysis in preclinical research, making it a logical target for anti‑obesity and metabolic studies. The term “AOD” stands for Anti‑Obesity Drug, reflecting its origin in pharmaceutical development programs led by Metabolic Pharmaceuticals Ltd. The objective was to create a compound capable of promoting fat loss while avoiding the systemic risks associated with full HGH therapy.

Structural and Functional Characteristics

• Composed of a short C‑terminal peptide sequence derived from HGH (growth hormone fragment 176–191).
• Designed to mimic the lipolytic domain of HGH while minimizing engagement of classic growth‑promoting pathways.
• Lacks the receptor‑binding regions responsible for most of HGH’s proliferative and growth‑factor effects.
• Developed to avoid significant activation of IGF‑1–mediated anabolic signaling in available studies.

Clinical Distinction

In contrast to recombinant HGH, which elevates IGF‑1 and can affect glucose metabolism and tissue growth, AOD‑9604 was designed with a narrower metabolic profile. In available preclinical and early clinical studies, AOD‑9604 did not meaningfully increase IGF‑1 levels or worsen standard markers of carbohydrate metabolism at the doses studied, differentiating it from full‑length HGH. This functional separation is critical: it positions AOD peptides as agents for metabolic research rather than as approved endocrine therapies. Long‑term, high‑dose safety data remain limited, and growth‑related endpoints such as tissue hypertrophy have not been characterized in large human trials.

Regulatory Status

AOD‑9604 is:

• Not approved as a therapeutic drug for weight loss or any indication by the FDA, EMA, or TGA.
• Classified as an investigational or discontinued obesity‑drug candidate in pharmacotherapy reviews.
• Distributed in some settings strictly as a research‑use compound or, in certain jurisdictions, as an ingredient in non‑drug products, which does not equate to drug approval.

How Does AOD-9604 Work? Mechanism of Action

Preclinical work indicates that AOD‑9604 modulates adipose‑tissue metabolism rather than acting as a general growth hormone.

Lipolysis and Adipose Response

In obese animal models, chronic AOD‑9604 exposure increased adipose lipolysis and reduced weight gain relative to controls. These effects have been linked to higher β3‑adrenergic receptor expression in adipose tissue, greater catecholamine sensitivity, and downstream activation of cAMP‑dependent, hormone‑sensitive lipase pathways that mobilize stored triglycerides.

Endocrine Profile

Early human data and pharmacotherapy reviews suggest that AOD‑9604 did not meaningfully increase IGF‑1 or worsen standard carbohydrate‑metabolism markers at studied doses, in contrast to full‑length HGH. However, phase 2b trials did not show clinically important weight‑loss benefits versus placebo, and the overall endocrine and safety profile remains incompletely characterized due to limited trial size and duration. AOD‑9604 was designed with a narrower metabolic profile than full-length HGH. Practitioners evaluating broader GH-axis stimulation approaches may find relevant mechanistic context in the CJC-1295 peptide guide.

AOD Peptide Benefits

For clinicians, the key question is how far AOD‑9604’s biological activity translates into real‑world outcomes. Current evidence supports metabolic activity but only modest clinical effects in humans.

Observed Effects in Preclinical and Clinical Settings

• Adipose Metabolism in Animal Models: In obese rodents, chronic oral administration of AOD‑9604 reduced weight gain and increased adipose lipolysis compared with controls, without a clear deterioration in glucose tolerance at the doses tested.
• Weight‑loss Signals in Early Trials: A 12‑week phase 2 trial reported that a 1 mg oral dose of AOD‑9604 produced an average weight loss of approximately 2.6 kg versus approximately 0.8 kg with placebo, a difference that was statistically significant but clinically modest.
• Efficacy Limits in Confirmatory Trials: A larger phase 2b program subsequently failed to demonstrate a statistically significant advantage of AOD‑9604 over placebo when combined with intensive lifestyle interventions, leading to discontinuation of obesity‑drug development.

Hormonal and Metabolic Profile

• IGF‑1 and Growth Signaling: Available data indicate that AOD‑9604 did not markedly increase IGF‑1 levels or trigger the broader growth‑factor changes seen with full‑length HGH, aligning with its design as a fragment focused on fat metabolism.
• Carbohydrate Metabolism: Trials and reviews describe a largely neutral effect on standard carbohydrate‑metabolism markers, with no consistent evidence of induced insulin resistance at clinical‑trial doses.
• Fluid Retention and Tissue Overgrowth: Clinically problematic fluid retention and acromegaly‑like changes have not been prominent features in the limited AOD‑9604 data sets, though the absence of long‑term post‑marketing surveillance means potential rare risks cannot be ruled out.

Clinical Context

In clinical discussions, AOD‑9604 is sometimes considered in the context of:

• Obesity and adiposity research.
• Body‑composition and fat‑distribution studies.
• Mechanistic work on GH fragments and adipose biology.

However, there is no robust evidence supporting localized ("spot") fat reduction with AOD‑9604. Fat metabolism remains a systemic process shaped by caloric balance, activity levels, and hormonal milieu; peptide‑driven effects, where present, appear modest compared with modern approved obesity pharmacotherapies. The Semaglutide guide covers the GLP-1 receptor agonist class for context on the scale of weight loss now achievable with approved agents.

AOD Peptide Dosage & Administration

Because AOD‑9604 is not an approved medication, there is no label‑defined dosing guidance for clinical use. Information about regimens comes from historical clinical trials and heterogeneous investigational or compounding practices.

Regimens Evaluated in Studies

Early obesity trials typically evaluated once‑daily oral doses of around 1 mg, given alongside diet and lifestyle programs, over 12–24 weeks. These studies showed modest, gradual weight‑loss differences versus placebo but did not demonstrate durable, phase‑3‑level efficacy, and phase 2b results failed to justify further development.

Practical Interpretation

• No AOD‑9604 regimen has been approved by regulators for weight‑management therapy.
• Any use in clinical practice occurs in investigational or compounded contexts and must be individualized by licensed prescribers in accordance with local law.
• Existing data do not support simple dose escalation to achieve larger effects; the limiting factor has been efficacy, not dose selection alone.

AOD-9604 Protocol

If AOD‑9604 is considered within a regulated investigational framework, typical monitoring considerations may include:

• Periodic assessment of weight, waist circumference, and body‑composition metrics.
• Routine metabolic panels (glucose, lipids) consistent with obesity‑pharmacotherapy monitoring.
• Documentation of any adverse events and concomitant therapies.

Because the long‑term risk profile is uncertain, periodic reassessment of risk–benefit rationale is critical.

Clinical Caution

Evidence supporting multi-peptide protocols remains limited and heterogeneous. Moreover, all combination use should occur under strict medical supervision and regulatory compliance.

Combination Protocols

AOD peptides are sometimes discussed alongside growth hormone secretagogues; the Ipamorelin guide covers its ghrelin receptor mechanism and protocol considerations for practitioners evaluating complementary GH-axis approaches. For practitioners evaluating dual-agonist approaches to metabolic disease, the Tirzepatide guide provides context on the GIP/GLP-1 class with established clinical data. Clinical evidence supporting multi-peptide protocols remains limited and heterogeneous. All combination use should occur under strict medical supervision and regulatory compliance.

AOD-9604 Side Effects

AOD‑9604 has generally been described as well‑tolerated in short‑term clinical studies, with adverse events that are usually mild. The safety database, however, is significantly smaller and less mature than that of approved obesity drugs.

Commonly Reported Reactions

Reported issues in clinical development and post‑hoc summaries include:

• Local or administration‑site reactions (e.g., redness, swelling, pruritus where applicable).
• Mild headache or fatigue, which typically resolved without intervention.

Safety Profile and Limitations

The absence of major safety signals in phase 2 programs does not equate to proof of long‑term safety for routine therapeutic use. Key limitations include:

• Modest sample sizes across trials compared with current GLP‑1 programs.
• Short treatment durations (on the order of weeks to months).
• Lack of phase 3 obesity trials and post‑marketing surveillance.

In addition, FDA has highlighted AOD‑9604 among bulk drug substances that may present significant safety risks in compounding due to limited safety information, potential immunogenicity, and reports of serious adverse events where causality is not always clear. Clinicians should therefore exercise caution when encountering compounded products that contain AOD‑9604.

Contraindications and Drug Interactions

Given the absence of high‑quality data:

• Use during pregnancy or breastfeeding is not recommended.
• Co‑administration with other metabolic agents (including GLP‑1 receptor agonists and other peptides) should be approached cautiously, with careful documentation of rationale, informed discussion, and local regulatory verification.

Because drug–drug interaction data are sparse, conservative decision‑making and close monitoring are advisable whenever AOD‑9604 is included in complex regimens.

AOD-9604 vs Other Compounds

AOD peptide is often informally compared with full HGH and GLP‑1 therapies because all three intersect with discussions of weight, adiposity, or body composition. The most clinically relevant comparison is not which agent is “strongest,” but which has the best combination of evidence, safety, and regulatory status for a given indication.

Parameter	AOD-9604	Full HGH	GLP-1 Agonists (e.g., Semaglutide)
Fat Loss Efficacy	Modest, research-based; failed to show clear benefit vs placebo in phase 2b obesity trials	Can reduce fat mass but with broader endocrine effects	High; large RCTs show substantial, sustained weight loss
Side Effects	Limited short-term data; mostly mild events reported	Systemic endocrine risks, fluid retention, IGF‑1 elevation	GI-related (nausea, vomiting, diarrhea); rare serious risks
IGF-1 Impact	Minimal	Significant increase	None
Cost	Moderate (research market)	High, indication- and region-dependent	Often high; varies by product and coverage
Prescription Status	Not approved	Prescription required (specific indications)	Prescription required (approved obesity indications)

• Compared to HGH: AOD‑9604 is more tightly focused on adipose metabolism and has not shown the same IGF‑1 elevations or classic HGH‑related adverse‑effect patterns at studied doses.
• Compared to GLP-1 agents: AOD‑9604’s weight‑loss efficacy is far weaker and less well validated; modern GLP‑1 and dual‑agonist trials demonstrate weight reductions an order of magnitude greater than AOD‑9604’s best‑case 12‑week signal.
• Best positioned as: A niche research compound rather than a mainstream obesity treatment.

Legal Status & Regulatory Considerations

AOD‑9604 is not FDA‑approved for therapeutic use and has never received marketing authorization as an obesity medication. Pharmacotherapy reviews list it among growth‑hormone analogues whose development was stopped after failing to show adequate efficacy in phase 2b trials.

Regulatory Highlights

• FDA and global regulators: No New Drug Application for AOD‑9604 has been approved, and the compound is not licensed as a prescription obesity therapy.
• Clinical development status: The original developer, Metabolic Pharmaceuticals, terminated the obesity program after phase 2b results failed to show statistically significant, clinically meaningful superiority over placebo.
• WADA: The World Anti‑Doping Agency explicitly names AOD‑9604 as a prohibited substance under section S2 of the current Prohibited List — specifically within the Growth Hormone Fragments subcategory — meaning it is banned for athlete use at all times. Note: WADA's original 2013 statement placed AOD‑9604 under S0 as a catch-all for unapproved substances before it was explicitly categorized; the current Prohibited List supersedes that classification.

In some jurisdictions, AOD‑9604 has been discussed as a food or cosmetic ingredient, but such listings do not confer drug status or imply approval as a treatment for obesity.

Clinical Implications

• AOD‑9604 cannot be marketed as an approved treatment for obesity, body composition, or performance enhancement.
• Any discussion with patients or research participants must acknowledge its unapproved status, limited evidence base, and regulatory restrictions.
• Practitioners must verify country‑ and state‑specific rules, including anti‑doping regulations, before considering any use.

Research Evidence Overview

Published work on AOD‑9604 has focused on its metabolic and lipolytic activities, particularly regarding the C‑terminal fragment of growth hormone and its effects on adipose tissue. Foundational studies by Ng et al. and Heffernan et al. helped define its mechanistic profile and preclinical efficacy. Subsequent clinical development generated:

• Shorter, phase 2 trials showing modest additional weight loss versus placebo at low oral doses.
• Larger, longer studies and pooled analyses that failed to confirm clinically meaningful fat‑loss effects, leading to abandonment of obesity‑drug development.

Taken together, the evidence supports biological activity in fat metabolism but does not support AOD‑9604 as a proven, stand‑alone obesity therapy.

Evidence Summary

• Demonstrates biologically relevant effects on adipose tissue metabolism in animal models and early human work.
• Lacks large‑scale, long‑term clinical validation showing superiority to placebo on standard obesity endpoints.
• Best conceptualized as an experimental GH‑fragment tool for metabolic research rather than an established clinical treatment.

FAQs — AOD Peptide

What does AOD stand for?

AOD stands for Anti‑Obesity Drug, referring to the compound’s original development goal in obesity research rather than an approved indication. AOD‑9604 is currently categorized as a research peptide and is not licensed as a prescription obesity medication.

Is AOD-9604 the same as HGH?

No. AOD‑9604 is a C‑terminal fragment of HGH focused on adipose‑tissue metabolism, while full‑length HGH is a systemic hormone with broad anabolic and metabolic effects. Their mechanisms, safety considerations, and regulatory status differ substantially, and AOD‑9604 does not share HGH’s approved indications.

How long before AOD-9604 shows results?

In a 12‑week obesity trial, weight‑loss differences between AOD‑9604 and placebo were modest and accumulated gradually over the study period. Responses were variable, and no large trials have demonstrated rapid, GLP‑1‑level weight reductions.

Can AOD-9604 be stacked with other peptides?

AOD‑9604 is sometimes discussed alongside peptides such as CJC‑1295 or Ipamorelin and with GLP‑1 receptor agonists, but controlled data on these combinations are extremely limited. Any combination use should be regarded as experimental and undertaken only under strict clinical and regulatory oversight.

Is AOD-9604 safe for women?

Available clinical data suggest general short‑term tolerability, but safety has not been fully established, and trials have not been powered to answer sex‑specific questions. It is contraindicated in pregnancy and breastfeeding, and use should remain within research or regulated contexts.

Final Considerations

The AOD peptide represents a targeted, mechanistically interesting approach to fat‑metabolism research, offering a distinct profile comspared with full‑length HGH and appetite‑suppressing drugs. Its selective lipolytic activity and relatively neutral short‑term metabolic profile make it scientifically noteworthy. At the same time, the lack of robust phase 3 data, abandonment of obesity‑drug development after phase 2b failure, and unapproved regulatory status preclude routine therapeutic use. For practitioners looking to shop AOD peptide within a research framework, sourcing from reputable, transparent suppliers who acknowledge the compound's investigational status and comply with local regulatory requirements is essential. Med Supply Solutions connects licensed practitioners with vetted research-grade suppliers — visit the peptides category for an overview of available compounds and sourcing options.

Citations

1. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res Paediatr. 2000;53(6):274‑278. doi:10.1159/000053183.
2. World Anti‑Doping Agency. WADA statement on substance AOD‑9604. WADA website. Published April 22, 2013. https://www.wada-ama.org/en/news/wada-statement-substance-aod-9604
3. Misra M. Obesity Pharmacotherapy: Current perspectives and future directions. Curr Cardiol Rev. 2013;9(1):33-54. doi:10.2174/157340313805076322
4. Heffernan M, Summers RJ, Thorburn A, et al. The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice andβ 3-AR Knock-Out Mice. Endocrinology. 2001;142(12):5182-5189. doi:10.1210/endo.142.12.8522
5. US Food and Drug Administration. Certain Bulk Drug Substances Used in Compounding May Present Significant Safety Risks. Updated April 21, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

Disclaimer

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.